Alfuzosin Hydrochloride extended release
Generic: ALFUZOSIN HYDROCHLORIDE
Basic Information
Manufacturer
Cipla USA Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
ORAL
FDA Set ID
3cc028d5-309f-4ce3-a2d7-5804ab57677d
Indications & Usage
1 INDICATIONS AND USAGE Alfuzosin hydrochloride extended-release tablet USP, is an alpha adrenergic antagonist, indicated for treatment of signs and symptoms of benign prostatic hyperplasia.
( 1 ) Important Limitations of Use: Alfuzosin hydrochloride is not indicated for the treatment of hypertension.
( 1.1 ) Alfuzosin hydrochloride is not indicated for use in the pediatric population.
( 1.1 , 8.4 , 12.3 ) Alfuzosin hydrochloride tablets USP, are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
1.1 Important Limitations of Use Alfuzosin hydrochloride is not indicated for the treatment of hypertension.
Alfuzosin hydrochloride is not indicated for use in the pediatric population.
( 1 ) Important Limitations of Use: Alfuzosin hydrochloride is not indicated for the treatment of hypertension.
( 1.1 ) Alfuzosin hydrochloride is not indicated for use in the pediatric population.
( 1.1 , 8.4 , 12.3 ) Alfuzosin hydrochloride tablets USP, are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
1.1 Important Limitations of Use Alfuzosin hydrochloride is not indicated for the treatment of hypertension.
Alfuzosin hydrochloride is not indicated for use in the pediatric population.
Adverse Reactions
6 ADVERSE REACTIONS Most common adverse reactions in clinical studies (incidence ≥2 % and at a higher incidence than placebo): dizziness, upper respiratory tract infection, headache, fatigue.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd.
at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The incidence of adverse reactions has been ascertained from 3 placebo-controlled clinical trials involving 1,608 men where daily doses of 10 and 15 mg alfuzosin were evaluated.
In these 3 trials, 473 men received alfuzosin hydrochloride 10 mg extended-release tablets.
In these trials, 4% of patients taking alfuzosin hydrochloride 10 mg extended-release tablets withdrew from the trial due to adverse reactions, compared with 3% in the placebo group.
Table 1 summarizes adverse reactions that occurred in ≥2% of patients receiving alfuzosin hydrochloride, and at a higher incidence than that of the placebo group.
In general, the adverse reactions seen in long-term use were similar in type and frequency to the events described below for the 3-month trials.
Table 1 - Adverse Reactions Occurring in ≥2% of Alfuzosin Hydrochloride Treated Patients and More Frequently than with Placebo in 3-Month Placebo-Controlled Clinical Trials The following adverse reactions, reported by between 1 % and 2% of patients receiving alfuzosin hydrochloride and occurring more frequently than with placebo, are listed alphabetically by body system and by decreasing frequency within body system: Body as a whole : pain Gastrointestinal system : abdominal pain, dyspepsia, constipation, nausea Reproductive system : impotence Respiratory system: bronchitis, sinusitis, pharyngitis Signs and Symptoms of Orthostasis in Clinical Trials : The adverse reactions related to orthostasis that occurred in the double-blind phase 3 trials with alfuzosin 10 mg are summarized in Table 2.
Approximately 20% to 30% of patients in these trials were taking antihypertensive medication.
Table 2 - Number (%) of Patients with Symptoms Possibly Associated with Orthostasis in 3-Month Placebo-Controlled Clinical Trials Testing for blood pressure changes or orthostatic hypotension was conducted in three controlled studies.
Decreased systolic blood pressure (≤90 mm Hg, with a decrease ≥20 mm Hg from baseline) was observed in none of the 674 placebo patients and 1 (0.2%) of the 469 alfuzosin hydrochloride patients.
Decreased diastolic blood pressure (≤50 mm Hg, with a decrease ≥15 mm Hg from baseline) was observed in 3 (0.4%) of the placebo patients and in 4 (0.9%) of the alfuzosin hydrochloride patients.
A positive orthostatic test (decrease in systolic blood pressure of ≥20 mm Hg upon standing from the supine position) was seen in 52 (7.7%) of placebo patients and in 31 (6.6%) of the alfuzosin hydrochloride patients.
6.2 Post-Marketing Experience The following adverse reactions have been identified during post approval use of alfuzosin hydrochloride.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General disorders: edema Cardiac disorders : tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation Gastrointestinal disorders : diarrhea, vomitting Hepatobiliary disorders : hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation) Respiratory system disorders : rhinitis Reproductive system disorders : priapism Skin and subcutaneous tissue disorders : rash, pruritis, urticaria, angioedema,toxic epidermal necrolysis Vascular disorders : flushing Blood and lymphatic system disorders : thrombocytopenia During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in some patients on or previously treated with alpha adrenergic antagonists [ see Warnings and Precautions ( 5.6 )].
Image Image
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd.
at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The incidence of adverse reactions has been ascertained from 3 placebo-controlled clinical trials involving 1,608 men where daily doses of 10 and 15 mg alfuzosin were evaluated.
In these 3 trials, 473 men received alfuzosin hydrochloride 10 mg extended-release tablets.
In these trials, 4% of patients taking alfuzosin hydrochloride 10 mg extended-release tablets withdrew from the trial due to adverse reactions, compared with 3% in the placebo group.
Table 1 summarizes adverse reactions that occurred in ≥2% of patients receiving alfuzosin hydrochloride, and at a higher incidence than that of the placebo group.
In general, the adverse reactions seen in long-term use were similar in type and frequency to the events described below for the 3-month trials.
Table 1 - Adverse Reactions Occurring in ≥2% of Alfuzosin Hydrochloride Treated Patients and More Frequently than with Placebo in 3-Month Placebo-Controlled Clinical Trials The following adverse reactions, reported by between 1 % and 2% of patients receiving alfuzosin hydrochloride and occurring more frequently than with placebo, are listed alphabetically by body system and by decreasing frequency within body system: Body as a whole : pain Gastrointestinal system : abdominal pain, dyspepsia, constipation, nausea Reproductive system : impotence Respiratory system: bronchitis, sinusitis, pharyngitis Signs and Symptoms of Orthostasis in Clinical Trials : The adverse reactions related to orthostasis that occurred in the double-blind phase 3 trials with alfuzosin 10 mg are summarized in Table 2.
Approximately 20% to 30% of patients in these trials were taking antihypertensive medication.
Table 2 - Number (%) of Patients with Symptoms Possibly Associated with Orthostasis in 3-Month Placebo-Controlled Clinical Trials Testing for blood pressure changes or orthostatic hypotension was conducted in three controlled studies.
Decreased systolic blood pressure (≤90 mm Hg, with a decrease ≥20 mm Hg from baseline) was observed in none of the 674 placebo patients and 1 (0.2%) of the 469 alfuzosin hydrochloride patients.
Decreased diastolic blood pressure (≤50 mm Hg, with a decrease ≥15 mm Hg from baseline) was observed in 3 (0.4%) of the placebo patients and in 4 (0.9%) of the alfuzosin hydrochloride patients.
A positive orthostatic test (decrease in systolic blood pressure of ≥20 mm Hg upon standing from the supine position) was seen in 52 (7.7%) of placebo patients and in 31 (6.6%) of the alfuzosin hydrochloride patients.
6.2 Post-Marketing Experience The following adverse reactions have been identified during post approval use of alfuzosin hydrochloride.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General disorders: edema Cardiac disorders : tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation Gastrointestinal disorders : diarrhea, vomitting Hepatobiliary disorders : hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation) Respiratory system disorders : rhinitis Reproductive system disorders : priapism Skin and subcutaneous tissue disorders : rash, pruritis, urticaria, angioedema,toxic epidermal necrolysis Vascular disorders : flushing Blood and lymphatic system disorders : thrombocytopenia During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in some patients on or previously treated with alpha adrenergic antagonists [ see Warnings and Precautions ( 5.6 )].
Image Image